Paraneoplastic Neurological Disorders, Volume 200 covers new, recent descriptions of autoantibodies against neuronal cell surface antigens (only partly associated with paraneoplastic disorders) and the introduction of new immuno-oncological drugs that can contribute to diseases that are pathogenetically indistinguishable from paraneoplastic syndromes. Besides investigating the pathogenetic mechanisms of these disorders, this book also explores what the introduction of new drugs used in immune checkpoint inhibitor cancer therapy are teaching us in terms of immunopathogenesis. Following sections present individual syndromes (phenotypical clinical manifestations) of the CNS, PNS, NMJ, and muscle.
Finally, the book investigates the role of antibody markers that differentiate by cytoplasmic, nuclear, and neuronal cell surface reactivities. Side effects of the new immuno-oncological drugs increasingly used in cancer therapy are also covered.
- Profiles paraneoplastic diseases by tumor type
- Identifies the pathogenetic mechanisms of PNS and provides epidemiological analysis
- Presents individual syndromes of the CNS, PNS, NMJ, and muscle
- Investigates the role of antibody markers
- Differentiates cytoplasmic, nuclear, and neuronal cell surface reactivities
- Discusses immune-oncological drugs causing diseases that are indistinguishable from PNS
- Reviews therapeutic strategies and clinical approach to PNS patients
- Head, Department of Neurology, Azienda Provinciale per I Servizi Sanitari (APSS) and University of Trento - Santa Chiara Hospital - 33100 TRENTO
- Coordinator of a European Commission project on Paraneoplastic Neurological Syndromes (Concerted Action –PNS EURONETWORK – Fifth Framework Programme QLG1-CT-2002-01756).
- Coordinator of a Specific Support Action of the European Commission on Paraneoplastic Neurological Syndromes (Sixth Framework Programme LSSM-CT-2005-518174).
- Former Vice President of the Italian Neurological Society (SIN)
Sean Pittock, M.D., is a consultant in the Department of Neurology and has a joint appointment in the Department of Laboratory Medicine and Pathology. He holds the academic rank of professor of neurology, Mayo Clinic College of Medicine. He currently serves as director of the Neuroimmunology Laboratory and is the Marilyn A. Park and Moon S. Park, M.D., Director of the Center for Multiple Sclerosis and Autoimmune Neurology. He joined the staff of Mayo Clinic in 2005.
Dr. Pittock’s research and clinical interests include autoimmune neurological disorders, paraneoplastic diseases, neuromyelitis optica and multiple sclerosis. His research focuses on the diagnosis and treatment of multiple sclerosis and autoimmune disorders that target the central and peripheral nervous systems. He founded the Autoimmune Neurology Clinic at Mayo Clinic in 2006, which has allowed the development of a unique translational practice extending the laboratory's serological findings directly from bench to bedside. He has been involved in cutting edge trials of novel immunotherapies to treat NMO and other autoimmune neurologic diseases. He has been invited to give over 100 presentations on his research and has authored over 275 journal articles, abstracts and other written publications.
He is currently the Chair of the Autoimmune Neurology Special Interest Group at the American Neurological Association and directs the educational program on Neuromyelitis Optica at the American Academy of Neurology.
Dr. Pittock serves on numerous professional societies and associations, including the Minnesota Medical Association and American Academy of Neurology, and is a committee member of the American Neurological Association.
